MBOAT1 Promotes Glioma Progression Through Enhancing Ferroptosis Resistance and Immunosuppressive Microenvironment

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Ferroptosis, a cell death pathway involving lipid peroxidation, is a potential therapeutic strategy for glioma.
• The MBOAT family's role in ferroptosis, particularly in glioma, is largely unknown.

Purpose of the Study:

• To investigate the role and clinical significance of MBOAT1 in glioma.
• To explore the underlying mechanisms by which MBOAT1 influences glioma progression, ferroptosis, and the tumor immune microenvironment.

Main Methods:

• Systematic analysis of MBOAT1 expression and clinical correlation using TCGA, CGGA, GEO, and GTEx databases.
• Functional investigation via enrichment analyses, single-cell RNA sequencing, and immune infiltration analysis.
• Experimental validation of MBOAT1's oncogenic role in glioblastoma (GBM) using in vivo and in vitro models.

Main Results:

• Elevated MBOAT1 expression in glioma correlates with higher tumor grade and poorer prognosis, identifying it as an independent prognostic factor.
• MBOAT1 is associated with increased ferroptosis resistance and promotes an immunosuppressive tumor microenvironment.
• Overexpression of MBOAT1 enhances GBM cell proliferation, migration, invasion, and ferroptosis resistance, while knockdown yields opposite effects.

Conclusions:

• MBOAT1 promotes glioma progression through ferroptosis resistance and modulation of the tumor immune microenvironment.
• MBOAT1 represents a potential independent prognostic biomarker for glioma.
• MBOAT1 emerges as a promising therapeutic target for glioma treatment.